Study S001410

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obese Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04440345
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 60
Start: 2020-06-16
Primary completion: 2021-06-16
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Overweight or Obesity
Interventions: DRUG:IBI362; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Number of treatment adverse events [From the time of first dosing (Day 1 ) until completion of the post treatment follow-up visit (20 week)]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013351	Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. Ji L, EClinicalMedicine	2022	Randomized trial	PMID 36247927 DOI	cites ClinicalTrials.gov:NCT04440345; registry reference DERIVED:36247927
R0013688	ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 mg and 10 mg in Chinese Adults with Overweight or Obesity , Journal of the Endocrine Society	2022	Randomized trial		cites ClinicalTrials.gov:NCT04440345
R0043672	ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 mg and 10 mg in Chinese Adults with Overweight or Obesity Linong Ji, Journal of the Endocrine Society	2022	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04440345
R0014885	IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. Ji L, EClinicalMedicine	2021	Randomized trial	PMID 34430840 DOI	cites ClinicalTrials.gov:NCT04440345; registry reference DERIVED:34430840